The Momentum Continues at the BIO CEO & Investor Digital Conference
Yesterday, business leaders from across the biopharma industry tuned in for a full day of engaging discussions and critical insights. Great meeting activity has also been underway in the BIO One-on-One Partnering™ system with nearly 900 delegates participating from more than 39 countries.
Today, the momentum continues with panel discussions, fireside chats, hundreds of company
presentations, and another exciting networking hour at 1:00-2:00PM EST with your colleagues!
Schedule of Events: Wednesday, February 17
Tip: The links below take you directly to sessions in the BIO Education Platform. Please make sure you are logged in to access each session.
Please note all session times below are in Eastern Standard Time (EST):
Clinical Success Rates and What is Driving Them
9:00AM - 9:45AM EST
Join Informa, QLS, and BIO for a discussion on the key findings from their new report on industry clinical success rates, including comparisons of success rates across indications and modalities, regulatory factors, timing of clinical phase transitions, and more.
CRISPR’s Progress for Patients: Clinical Development of Therapies
10:00AM - 10:30AM EST
This fireside chat with the CEO of Spotlight Therapeutics will explore the current frontier of clinical progress by CRISPR-based therapeutic approaches across a variety of indications, as well as new opportunities soon to be unlocked by next-gen CRISPR technologies.
Investors' Reactions to Reference Pricing Models
10:30AM - 11:55AM EST
RA Capital’s Peter Kolchinsky will open this TWO-PART session that examines the narrowing in investor support for therapeutic innovation that reference pricing systems would cause by changing the relative risk valuations within biopharma portfolios versus alternative investments. A panel on pending public policy proposals on pricing proceeds post Peter’s presentation.
Fireside Chat: Adam Koppel, MD, PhD, Managing Director, Life Sciences, Bain Capital, LP
12:00PM - 1:00PM EST
Adam M. Koppel rejoined Bain Capital in 2016 as Managing Director of Bain Capital Life Sciences after serving as Biogen’s EVP of Corporate Development and Chief Strategy Officer. Adam will be interviewed by experienced transactions lawyer Neal J. Reenan, Partner, Latham & Watkins LLP.
Join us today from 1:00 - 2:00PM EST to interact live with a new group of companies!
Investors and attendees can connect via video conferencing for face-to-face discussion with presenting companies. Access these networking opportunities via the "Networking Pavilion" in the BIO Education Platform. Simply click the link to join, complete your profile and enter the room to start networking! Here is a Quick Start Guide to Networking.
Policy Outlook: Reviewing the Pathway for Advancing Biopharma Goals in Congress and the White House
2:00PM - 3:00PM EST
With the arrival of a new administration, access to medicines and advancing innovation remain key goals for the industry. Hear the latest perspective from experts within the Beltway and company executives to prepare for the next four years.
Turning RNA Research into Medicines
3:00PM - 4:00PM EST
RNA research has long claimed to be a disruptive treatment opportunity, utilizing carefully designed molecules to prompt the body to make its own medicine. Hear from drug developers and scientists as they share their stories and what's to come to realize the long-term vision.
Market Outlook: Breaking More Records or Expecting a Releveling?
4:00PM - 5:00PM EST
In July, the U.S. economy suffered from a 32.9% contraction in GDP, the largest in recent history. Despite a partial bounce back, biotech venture funding, IPOs, and biotech stock indexes have reached record highs in 2020. Attend to hear success stories and challenges as economic, political, and public health uncertainty rise even higher than 6 months ago.
Missed a session?
Check out the BIO CEO & Investor Digital Conference Live Blog bringing you conference and social media highlights, or watch any time on-demand until March 16.